Inovio Pharmaceuticals Continues to Sink Lower
Shares of Inovio Pharmaceuticals (NASDAQ: INO) tumbled as much as 18% today as investors try to figure out exactly how the business fits in with global efforts to combat the coronavirus pandemic. After becoming one of the faces of early efforts to develop a vaccine, the stock has fallen by more than half since its peak earlier this month.
It appears investors are coming to grips with the long odds facing the company, which has never successfully developed nor commercialized a drug product. Inovio Pharmaceuticals could still bring a viable SARS-CoV-2 vaccine to market, but it will take another year or so in a best case scenario.
As of 3:45 p.m. EDT, the pharma stock had settled to a 13.2% loss.
Source Fool.com
